AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors

 
• By Sten Stovall
  
Data
AstraZeneca, FibroGen will start talks soon with the FDA aimed at regulatory submissions of roxadustat • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D